{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ08516",
      "entity_text" : "YLB113",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ06273",
      "entity_text" : "ACR50",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "ACR50 (the same instrument as ACR20, with improvement levels defined as 50% instead of 20%) response rates increased over time, with 20.1% of patients in the YLB113 arm and 23.2% in the RP arm achieving ACR50 responses at week 4, and 56.5 and 67.5% in the YLB113 and RP arms, respectively, achieving ACR50 responses at week 24.",
  "reading_complete" : "2020-07-28T18:41:40Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T18:38:50Z",
  "trigger" : "increased",
  "evidence" : [ "ACR50 (the same instrument as ACR20, with improvement levels defined as 50% instead of 20%) response rates increased over time, with 20.1% of patients in the YLB113 arm and 23.2% in the RP arm achieving ACR50 responses at week 4, and 56.5 and 67.5% in the YLB113" ],
  "pmc_id" : "7021908",
  "score" : 0
}